NCT04902885 - Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

December 29, 2021

Study Completion Date

December 31, 2022

Conditions

Extensive-stage Small-cell Lung Cancer

Interventions

DRUG

Trilaciclib, carboplatin, etoposide，or Topotecan

Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients

DRUG

placebo, carboplatin, etoposide，or Topotecan

placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients

Trial Locations (1)

Jilin Cancer Hopspital, Changchun